Overview

* Immunic ( IMUX ) reports Q3 net loss of $25.6 mln, with insufficient cash for 12 months

* R&D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024

Outlook

* Company expects top-line data from phase 3 ENSURE trials by end of 2026

* Company preparing further clinical testing of IMU-856, contingent on financing

Result Drivers

* EMPhASIS TRIAL - Long-term phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients free of confirmed disability worsening and favorable safety

* PATENT PROTECTION - Received Notice of Allowance from USPTO for patent covering vidofludimus calcium dose strengths, potentially extending U.S. market exclusivity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$25.58

Income mln

Q3 Basic -$0.13

EPS

Q3 -$25.99

Income mln

From

Operatio

ns

Q3 $25.99

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunic Inc ( IMUX ) is $4.00, about 81% above its November 12 closing price of $0.76

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)